Allspring Global Investments’s Syndax Pharmaceuticals SNDX Stock Holding History

Allspring Global Investments’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$467K	Buy	19,564 +2,002	+11%	+$43.5K	﹤0.01%	1405
2025 Q4	$374K	Buy	17,562 +1,455	+9%	+$25.4K	﹤0.01%	1457
2025 Q3	$253K	Buy	+16,107	New	+$211K	﹤0.01%	1517
2023 Q3	–	Sell	-2,501	Closed	-$52.3K	–	2888
2023 Q2	$52.3K	Sell	2,501 -6,470	-72%	-$135K	﹤0.01%	2281
2023 Q1	$189K	Buy	8,971 +4,435	+98%	+$110K	﹤0.01%	1834
2022 Q4	$115K	Sell	4,536 -123	-3%	-$2.87K	﹤0.01%	2023
2022 Q3	$111K	Buy	4,659 +4,479	+2,488%	+$100K	﹤0.01%	2045
2022 Q2	$3K	Buy	+180	New	+$3K	﹤0.01%	2637

Other funds holding SNDX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Allspring Global Investments's SNDX Position: Q1 2026 in Review

Allspring Global Investments increased its Syndax Pharmaceuticals (SNDX) stake by 11% in Q1 2026, buying an estimated $43.5K and bringing the position to 19,564 shares worth $467K. The position accounts for ﹤0.01% of the portfolio, ranked #1405.

Allspring Global Investments first reported a position in SNDX in Q2 2022 and has held it in 8 quarters since. 247 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.

Allspring Global Investments held 19,564 shares of Syndax Pharmaceuticals worth $467K as of Q1 2026.
Allspring Global Investments bought 2,002 Syndax Pharmaceuticals shares in Q1 2026, an estimated $43.5K.
Syndax Pharmaceuticals made up ﹤0.01% of Allspring Global Investments's portfolio in Q1 2026, its #1405 holding.
Allspring Global Investments first reported a position in Syndax Pharmaceuticals in Q2 2022 and has held it in 8 quarters since.
247 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.

Based on Allspring Global Investments's 13F filing for Q1 2026, filed 5 May 2026.